AP-1 plays key role in various AML subtypes, team says

Print Friendly, PDF & Email


Micrograph showing AML
Image from Armed Forces Institute of Pathology
The AP-1 transcription factor family is of “major importance” in acute myeloid leukemia (AML), according to researchers. The team said they identified transcription factor networks specific to AML subtypes, which showed that leukemic growth is dependent upon certain transcription factors, and “the global activation... [Read Article]
Print Friendly, PDF & Email

Combo appears safe, active in rel/ref NHL

Print Friendly, PDF & Email


Micrograph showing
follicular lymphoma
The combination of Hu5F9-G4 (5F9) and rituximab was considered safe and produced durable complete responses (CRs) in patients with relapsed or refractory non-Hodgkin lymphoma (NHL) in a phase 1b trial. Mainly low-grade adverse events (AEs) were observed with rituximab and 5F9, a macrophage-activating immune checkpoint inhibitor blocking CD47. In addition,... [Read Article]
Print Friendly, PDF & Email

Palliative care guidelines relevant for hematologists, doc says

Print Friendly, PDF & Email


Husband holding hands
with wife in hospital
Photo from Pexels
The latest edition of the national palliative care guidelines provides new clinical strategies relevant to hematology practice in the United States, according to a physician-researcher specializing in hematology. The guidelines represent a “blueprint for what it looks like to provide high-quality, comprehensive palliative care... [Read Article]
Print Friendly, PDF & Email

Links between SCT and adverse outcomes

Print Friendly, PDF & Email


Rakhi P. Naik, MD
Photo by Jon Christofersen
Although sickle cell trait (SCT) has been linked to adverse clinical outcomes in multiple studies, only a handful of associations have strong evidence supporting them, according to a systematic review. Evidence was strongest for the association between SCT and venous and renal complications. There was low-strength... [Read Article]
Print Friendly, PDF & Email

SNPs linked to bleeding in African Americans on warfarin

Print Friendly, PDF & Email


Warfarin tablets
Researchers say they have identified single-nucleotide polymorphisms (SNPs) that are associated with increased bleeding risk in African-American patients on warfarin. A retrospective study revealed four SNPs associated with increased bleeding risk in African Americans with an international normalized ratio (INR) of less than 4. One of these SNPs was seen in more... [Read Article]
Print Friendly, PDF & Email

CTPA overused in veterans with suspected PE

Print Friendly, PDF & Email


CTPA showing PE
Image from Medical
College of Georgia
The recommended approach to evaluating suspected pulmonary embolism (PE) is “greatly underutilized” in the Veterans Health Administration system, according to a speaker at CHEST 2018. A survey showed that, contrary to guideline recommendations, most Veterans Affairs sites did not require incorporation of a clinical decision rule... [Read Article]
Print Friendly, PDF & Email

Obese PE patients have lower risk of death

Print Friendly, PDF & Email


Woman on a scale
Patients with pulmonary embolism (PE) have a lower mortality risk if they are obese, according to a retrospective analysis of nearly 2 million PE discharges. The obese patients had a lower mortality risk despite receiving more thrombolytics and mechanical intubation, said study investigator Zubair Khan, MD, of the University of... [Read Article]
Print Friendly, PDF & Email

Bacteremic sepsis in ALL tied to neurocognitive dysfunction

Print Friendly, PDF & Email


Child with leukemia
Photo by Bill Branson
Bacteremic sepsis during acute lymphoblastic leukemia (ALL) treatment may contribute to neurocognitive dysfunction later in life, results of a cohort study suggest. Pediatric ALL survivors who had sepsis while on treatment performed worse on measures of intelligence, attention, executive function, and processing speed than survivors with... [Read Article]
Print Friendly, PDF & Email

New guidelines for idiopathic multicentric Castleman disease

Print Friendly, PDF & Email


David C. Fajgenbaum, MD
Photo from Penn Medicine
The anti-IL-6 antibody siltuximab is central to first-line treatment of idiopathic multicentric Castleman disease (iMCD), according to new guidelines on iMCD published in Blood. The guidelines also say that early intervention with combination chemotherapy may prevent a fatal outcome in patients with severe iMCD. To create... [Read Article]
Print Friendly, PDF & Email

CAR T therapy being explored in Hodgkin lymphoma

Print Friendly, PDF & Email


Attendees at the NCCN
13th hematology congress
Photo courtesy of NCCN
Although the data set is small and not yet mature, chimeric antigen receptor (CAR) T-cell therapy appears to be a promising approach for Hodgkin lymphoma, according to Philippe Armand, MD, PhD, of Dana-Farber/Brigham and Women’s Cancer Center and the Massachusetts General Hospital Cancer... [Read Article]
Print Friendly, PDF & Email

Quadruplet therapy could be the future in MM

Print Friendly, PDF & Email


Attendees at the NCCN 13th
hematology congress
Photo courtesy of NCCN
Four-drug combinations are holding promise for the treatment of multiple myeloma (MM), although data from additional randomized trials are needed to define their role in clinical practice, according to Natalie S. Callander, MD, of the University of Wisconsin Carbone Cancer Center. The efficacy of... [Read Article]
Print Friendly, PDF & Email

BCMA-targeted platforms could alter MM therapy

Print Friendly, PDF & Email


Bone marrow aspirate
showing MM
Three novel treatment strategies that target B-cell maturation antigen (BCMA) are showing promise in recent multiple myeloma (MM) clinical trials, according to Shaji K. Kumar, MD, of Mayo Clinic Cancer Center in Rochester, Minnesota. “Clearly, there are a lot of exciting drugs that are currently in clinical trials, but these 3... [Read Article]
Print Friendly, PDF & Email

CK and TP53 status should be assessed together, team says

Print Friendly, PDF & Email


Mantle cell lymphoma
Researchers say they have found evidence to suggest that patients with mantle cell lymphoma (MCL) should be evaluated for TP53 mutation and complex karyotype (CK) simultaneously before treatment. The team’s study showed that TP53 mutation and CK occurred independently, but patients with both characteristics had poor prognosis. All patients with TP53... [Read Article]
Print Friendly, PDF & Email

Guidelines for proton therapy in mediastinal lymphomas

Print Friendly, PDF & Email


Treatment room at the
Roberts Proton Therapy
Center at the University
of Pennsylvania.
Photo from Penn Medicine
Proton therapy can help mitigate toxicity in adults with mediastinal lymphomas, but the treatment should only be used in patients expected to derive the most benefit, according to new guidelines from the International Lymphoma Radiation Oncology Group. The... [Read Article]
Print Friendly, PDF & Email

Risks of watchful waiting in follicular lymphoma

Print Friendly, PDF & Email


Micrograph showing
follicular lymphoma
A subset of follicular lymphoma (FL) patients managed with watchful waiting are vulnerable to organ dysfunction and transformation, according to research published in Clinical Lymphoma, Myeloma & Leukemia. In a retrospective study, about 24% of FL patients managed with watchful waiting developed significant organ dysfunction or transformation at first progression over... [Read Article]
Print Friendly, PDF & Email